
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is poised for success in the biotechnology market with its robust pipeline of high-value assets and potential for partnerships that will drive value creation for its novel vaccine technology. The company's recent collaboration with Sanofi has already resulted in $20 million in sales, further demonstrating the potential demand for its vaccine. With a differentiated tolerability profile and projected market share of 19-26% for its standalone COVID-19 vaccine, Novavax is well positioned for growth and has the potential to be a major player in the COVID-19 vaccine market.
Bears say
Novavax is a biotechnology company that is currently in its clinical stage of development, with a focus on developing novel vaccines for a wide range of diseases. The recent positive results from the COMPARE study, which compared its vaccine Nuvaxovid to mNEXSPIKE, have shown a potentially differentiated tolerability profile, supported by a 3rd party ICER draft evidence report. However, Novavax’s share in the vaccine market may be limited due to the competitive landscape and potential risks such as failure to successfully develop a combo vaccine, potential eradication of the virus, and negative regulatory developments. Additionally, Novavax’s long-term success hinges on the successful development and commercialization of its Matrix-M adjuvant technology.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares